PURPOSE: The aim of this study was to evaluate, by means of (123)I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. METHODS: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. RESULTS: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53+/-0.58 versus 1.73+/-0.45 on therapy, p<0.001), striatal( 123)I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. CONCLUSION: The results of this study suggest that levodopa does not affect( 123)I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.
PURPOSE: The aim of this study was to evaluate, by means of (123)I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson's disease. METHODS: Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest-occipital)/occipital. RESULTS: During levodopa wash-out, despite a worsening in patients' clinical disability (H&Y mean stage 2.53+/-0.58 versus 1.73+/-0.45 on therapy, p<0.001), striatal( 123)I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined. CONCLUSION: The results of this study suggest that levodopa does not affect( 123)I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.
Authors: K Tatsch; S Asenbaum; P Bartenstein; A Catafau; C Halldin; L S Pilowsky; A Pupi Journal: Eur J Nucl Med Mol Imaging Date: 2002-10 Impact factor: 9.236
Authors: Françoise J Siepel; Arvid Rongve; Tirza C Buter; Mona K Beyer; Clive G Ballard; Jan Booij; Dag Aarsland Journal: BMJ Open Date: 2013-04-08 Impact factor: 2.692
Authors: Susanne Nikolaus; Markus Beu; Angelica Maria De Souza Silva; Joseph P Huston; Hubertus Hautzel; Owen Y Chao; Christina Antke; Hans-Wilhelm Müller Journal: Front Behav Neurosci Date: 2014-12-17 Impact factor: 3.558
Authors: Susanne Nikolaus; Markus Beu; Hubertus Hautzel; Angelica M De Souza Silva; Christina Antke; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller Journal: Nucl Med Commun Date: 2013-12 Impact factor: 1.690